Guess which ASX All Ords share is soaring 12% on a 'key step'

A positive update is getting investors very excited. What did the company announce?

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Race Oncology Ltd (ASX: RAC) share price is having a very strong session.

In morning trade, the ASX All Ords share is up an impressive 12% to 86 cents.

Why is this ASX All Ords share rising?

Investors have been buying the oncology company's shares after it released an update on its novel bisantrene formulation, RC220.

According to the release, the company has successfully completed a series of preclinical animal and laboratory studies showing that RC220 prevents drug precipitation (crystallisation) and phlebitis (vein inflammation or damage) when infused into peripheral veins.

These studies were performed in vivo and in vitro at Pharmaron in California and by Race Oncology scientists at the University of Wollongong.

Why is this important?

The current administration of bisantrene requires the use of an invasive central venous catheter and must be performed in a hospital setting.

While this approach is common practice for the delivery of chemotherapy drugs in patients with haematological cancers, it is not standard practice for solid tumours, such as breast cancer, where peripheral IV infusions in an outpatient setting are typically preferred by both the patient and the treating oncologist.

RC220 could potentially open the door to bisantrene being administered in an outpatient setting.

The ASX All Ords share' executive director, Dr Pete Smith, was pleased with the news. He commented:

Given the creativity, hard work and capital we have invested into RC220, it is gratifying to see the formulation perform as designed, preventing bisantrene peripheral vein precipitation and phlebitis in industry standard preclinical models expected by regulators. This is a key step on our path to bringing a superior version of bisantrene to the clinic for the benefit of a much larger number of patients with solid tumours and the clinicians who treat them. With RC220 also comes additional, robust intellectual property that adds significant commercial value to Race.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Here's why this ASX 200 healthcare stock is roaring 13% higher on Wednesday

This healthcare company is outperforming every other stock within the ASX 200 today.

Read more »

A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop

Could CSL stock be a millionaire-maker at $261

Does the exceptional biotech company still harness the power to make an investment today worth a million in the future?

Read more »

Two happy scientists analysing test results in a lab
Healthcare Shares

Why are Mesoblast shares charging 5% higher today?

This beaten down biotech is having a strong session. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Healius share price rallies amid corporate reset

An outgoing chair and a revitalised balance sheet. Healius is undergoing a makeover.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Imugene share price jumps 32% on FDA news

Here's why this biotech is having a strong start to the session.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Healthcare Shares

Broker tips big gains and yields from NIB shares

Goldman Sachs is saying good things about this health insurance provider.

Read more »

A man with grahpics of robot arms, indicating a share price movement in ASX robotics and tech companies
Healthcare Shares

Up 784% in 5 years, why this ASX 200 healthcare share has a 'clear pathway' for growth in 2024

The ASX 200 stock has been a standout performer within the healthcare sector.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Healthcare Shares

Why are Healius shares crashing 35% on Wednesday?

This healthcare share is crashing deep into the red on Wednesday. What's happening?

Read more »